within Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H05B_AntiParathyroidAgents.H05BX05_Calcifediol;
model Calcifediol 
   extends Pharmacolibrary.Drugs.ATC.H.H05BX05;

  annotation(Documentation(
    info ="<html><body><p>Calcifediol, also known as 25-hydroxyvitamin D3, is a prohormone of the active form of vitamin D. It is used in the management of vitamin D deficiency and in certain cases of chronic kidney disease to treat secondary hyperparathyroidism. The drug is approved and commonly used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Reported in healthy adult subjects following single oral administration.</p><h4>References</h4><ol><li><p>Jetter, A, et al., &amp; Bischoff-Ferrari, HA (2014). Pharmacokinetics of oral vitamin D(3) and calcifediol. <i>Bone</i> 59 14–19. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24516879/&quot;>https://pubmed.ncbi.nlm.nih.gov/24516879</a></p></li><li><p>Petkovich, M, et al., &amp; Bishop, CW (2015). Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation. <i>The Journal of steroid biochemistry and molecular biology</i> 148 283–289. DOI:<a href=&quot;https://doi.org/10.1016/j.jsbmb.2014.11.022&quot;>10.1016/j.jsbmb.2014.11.022</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25446887/&quot;>https://pubmed.ncbi.nlm.nih.gov/25446887</a></p></li><li><p>Cesareo, R, et al., &amp; Palermo, A (2019). Hypovitaminosis D: Is It Time to Consider the Use of Calcifediol?. <i>Nutrients</i> 11(5) –. DOI:<a href=&quot;https://doi.org/10.3390/nu11051016&quot;>10.3390/nu11051016</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31064117/&quot;>https://pubmed.ncbi.nlm.nih.gov/31064117</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Calcifediol;
